Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stryker Corporation filings document the regulatory record of a New York Stock Exchange-listed medical technology issuer with operations in MedSurg, Neurotechnology and Orthopaedics. Its 8-K reports cover operating results, financial-condition updates, material events, Regulation FD disclosures and exhibits tied to company press releases.
The filing record also describes governance and capital-structure matters, including definitive proxy materials, annual-meeting votes, director elections, auditor ratification, executive-compensation votes, common stock and listed senior unsecured notes. Recent material-event filings include cybersecurity incident disclosures and amendments describing operational and reporting updates connected to Stryker's information technology environment.
Stryker Corporation granted Group President James Andrew Pierce new equity awards on February 4, 2026. He received 2,771 Restricted Stock Units (RSUs) that vest in three equal installments on March 21, 2027, March 21, 2028, and March 21, 2029, each RSU representing one share of common stock.
Pierce was also granted an employee stock option for 15,300 shares of Stryker common stock at an exercise price of $360.82 per share. The option becomes exercisable as to 20% of the shares on each of the first five anniversaries of the grant date and expires on February 3, 2036. After these awards, he holds 73,334 shares directly, plus additional indirect holdings through his sons and a 401(k) account.
Stryker Corporation reported that President and COO Spencer S. Stiles received an employee stock option grant on February 4, 2026. The grant covers 19,956 stock options with an exercise price of $360.82 per share, giving him the right to buy Stryker common stock at that price.
These options were issued under the Stryker Corporation 2011 Long-Term Incentive Plan and vest over time, becoming exercisable in 20% increments on each of the first five anniversaries of the grant date. The options expire on February 3, 2036, and are held directly by Stiles.
Stryker Corporation Chair and CEO Kevin Lobo reported several equity transactions and a new option grant. On February 6, 2026, he exercised 206,955 employee stock options at $96.64 per share, acquiring the same number of Stryker common shares.
That same day, 132,410 shares of common stock were disposed of at $362.42 per share in a transaction coded “F,” typically used for tax withholding, leaving him with 196,940 directly held shares plus 721 shares held indirectly via a 401(k). On February 4, 2026, he also received a new grant of 58,206 stock options with an exercise price of $360.82 per share, expiring on February 3, 2036.
Stryker Corporation’s President and COO, Spencer S. Stiles, reported option exercises and share dispositions. On 02/03/2026, he exercised 13,840 employee stock options at $96.64 per share, receiving the same number of common shares. That day, 7,692 common shares were disposed of at $368.14 per share. After these transactions, he held 68,982 common shares directly and 1,670 shares indirectly through a 401(k).
Stryker Corporation Group President James Andrew Pierce reported several share transactions on 02/02/2026. He exercised an employee stock option for 13,840 shares of Common Stock at $96.64 per share and acquired the underlying shares. To cover associated obligations, 8,432 shares of Common Stock were disposed of at $369.56 per share. He also sold 475 shares of Common Stock in open-market transactions at a weighted average price of $368.873 per share, with individual trades ranging from $368.7534 to $368.92. After these transactions, he directly owned 70,563 shares of Common Stock and held indirect interests in 712 shares and 713 shares through his sons and 1,595 shares through a 401(k) plan. The option grant from 02/10/2016 was fully exercised, leaving 0 derivative securities outstanding from that grant.
Stryker Corporation insider plans a small stock sale under Rule 144. A holder intends to sell 475 shares of Stryker common stock through UBS Financial Services on or about 02/02/2026 on the NYSE, with an aggregate market value listed as 175,214.
The 475 shares were acquired on 02/02/2026 by exercising an option with payment made by wire transfer to Stryker Corp. The filing notes that the filer represents they are not aware of any undisclosed material adverse information about Stryker’s current or prospective operations.
Stryker Corporation filed a current report to note that it issued a press release on January 29, 2026 announcing its fourth quarter and full-year 2025 operating results and 2026 outlook. The press release is furnished as Exhibit 99.1 and is not treated as filed for liability purposes under the Exchange Act.
Stryker Corporation director Andrew K. Silvernail reported equity transactions in the company’s stock. On January 15, 2026, he exercised a stock option for 4,570 shares of common stock at a price of $96.64 per share, granted under the Stryker Corporation 2011 Long-Term Incentive Plan, which vested in 20% increments over five years.
On the same date, he also disposed of 1,229 shares of common stock at a price of $359.39 per share, as reflected by transaction code “F” in the non-derivative table. Following these transactions, Silvernail directly owned 17,703 shares of Stryker common stock.
Stryker Corp director Ronda E. Stryker reported exercising a stock option and acquiring additional common shares. On 01/14/2026 she exercised a stock option granted on 02/10/2016 for 4,570 shares of common stock at an exercise price of $96.64 per share. Following this transaction, she directly owned 5,783 shares of Stryker common stock.
The filing also lists significant indirect holdings of Stryker common stock. These include 13,578,805 shares held by the L. Lee Stryker Trust, 37,600 shares held by the 1988 William D. Johnston Trust, and 2,702,108 shares held by a Revocable Trust. The stock option was originally granted under the Stryker Corporation 2011 Long-Term Incentive Plan and became exercisable in 20% increments on each of the first five anniversaries of the grant date.
Stryker Corporation Group President Dylan Bram Crotty filed an initial ownership report detailing his equity holdings in SYK. As of 01/01/2026, he reports direct ownership of 5,842 shares of Stryker common stock, plus indirect holdings of 1,480 shares through a 401(k) plan and additional shares held via a personal trust and accounts for his daughter and son.
Crotty also reports a series of employee stock options granted between 2017 and 2025, covering thousands of shares at exercise prices ranging from $122.51 to $392.39 per share. Earlier grants are fully vested, while more recent grants become exercisable in 20% increments on each of the first five anniversaries of the grant date under Stryker’s 2011 Long-Term Incentive Plan.